Skip to main content
SpringerLink
Log in

Antiparkinsonian Agents

Clinically Significant Drug Interactions and Adverse Effects, and Their Management

  • Adverse Effects
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

The treatment of Parkinson’s disease for most patients entails long term exposure to multiple agents, including anticholinergics, levodopa, amantadine, dopamine receptor agonists, catechol-O-methyltransferase inhibitors, selegiline (deprenyl) and clozapine. Patients with Parkinson’s disease require medication for the control of the motor symptoms of their condition, for related medical or psychiatric symptoms of the disorder, and for concurrent medical problems, such as hypertension or cardiac disease.

All these agents may cause adverse effects. There is a potential for drug-drug interactions between different antiparkinsonian agents and between antiparkinsonian medication and the other drugs a patient may be taking. Clinicians caring for patients with Parkinson’s disease must be knowledgable about the potential adverse effects and drug interactions of an expanding array of medications for this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schoenberg BS. Epidemiology of movement disorders. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths, 1987: 17–32

    Google Scholar 

  2. Stockton P, Jones JK. Medication use by the elderly. Aging Clin Exp Res 1993; 5(5): 337–47

    CAS  Google Scholar 

  3. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211–4

    PubMed  CAS  Google Scholar 

  4. Pfeiffer RF. Antiparkinsonian agents: drug interactions of clinical significance. Drug Saf 1996; 14(5): 343–54

    Article  PubMed  CAS  Google Scholar 

  5. Charcot J-M. Lectures on the disease of the nervous system. London: New Sydenham Society, 1877

    Google Scholar 

  6. Cotzias GC, van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–9

    Article  PubMed  CAS  Google Scholar 

  7. Tune L, Carr S, Hong E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393–4

    PubMed  CAS  Google Scholar 

  8. Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man. Eur J Pharmacol 1976; 35: 293–9

    Article  PubMed  CAS  Google Scholar 

  9. Roberts J, Waller DG, von Renwick AG, et al. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 1996; 41: 331–7

    Article  PubMed  CAS  Google Scholar 

  10. Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest 1971; 1: 313–20

    Article  PubMed  CAS  Google Scholar 

  11. Gianutsos G, Chute S, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long term administration of amantadine. Eur J Pharmacol 1985; 110: 357–61

    Article  PubMed  CAS  Google Scholar 

  12. Nastuck WC, Su PC, Doublet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264: 76–9

    Article  Google Scholar 

  13. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol 1992; 94 Suppl.: S4–6

    Google Scholar 

  14. Pfeiffer RF. Amantadine-induced vocal myoclonus [letter]. Mov Disord 1996; 11(1): 104–51

    Article  PubMed  CAS  Google Scholar 

  15. Bleidner WE, Harman JB, Hewes WE, et al. Absorption, distribution, and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965; 150: 484–90

    PubMed  CAS  Google Scholar 

  16. Speeg KV, Leighton JA, Maldonoado AL. Case report: toxic delirium in a patient taking amantadine and trimethoprimsulfamethoxazole. Am J Med Sci 1989; 298: 410–2

    Article  PubMed  CAS  Google Scholar 

  17. Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can Med Assoc J 1983; 129: 974–5

    PubMed  CAS  Google Scholar 

  18. Kulig K, Moore LL, Kirk M, et al. Bromocriptine-associated headache: possible life-threatening sympathomimetic reaction. Obst Gynecol 1991; 78: 941–3

    CAS  Google Scholar 

  19. Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine in normal subjects [abstract]. Clin Pharmacol Ther 1990; 47: 166

    Article  Google Scholar 

  20. Sibley WA, Laguna JF. Enhancement of bromocriptine clinical effect and plasma levels with erythromycin. Excerpta Med 1981; 548: 329–30

    Google Scholar 

  21. Ayres J, Maseley MN. Alcohol increases bromocriptine side effects [letter]. N Engl J Med 1980; 302: 806

    Article  PubMed  CAS  Google Scholar 

  22. Schwinn G, Dirks H, McIntosh C, et al. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months. Eur J Clin Invest 1977; 7: 101–7

    Article  PubMed  CAS  Google Scholar 

  23. Andersen PK, Christensen KN, Hole P, et al. Sodium nitroprusside and epidural blockade to treat severe ergotism. N Engl J Med 1977; 296: 1271–3

    Article  PubMed  CAS  Google Scholar 

  24. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 1990; 39: 491–506

    Article  PubMed  CAS  Google Scholar 

  25. Piercey MF, Walker EL, Feldpausch DL, et al. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Let 1996; 219: 138–40

    CAS  Google Scholar 

  26. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease. Neurology 1997; 49: 162–8

    Article  PubMed  CAS  Google Scholar 

  27. Pharmacia and Upjohn Co. Mirapex package insert. Kalamazoo (MI): Pharmacia and Upjohn Co., Jun 1997

    Google Scholar 

  28. SmithKline Beecham. Requip package insert. Crawley, UK: SmithKline Beecham, Sep 1997

  29. Adler CH, Sethi KD, Davis TL, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurology 1997; 49: 393–9

    Article  PubMed  CAS  Google Scholar 

  30. Data on file, SmithKline Beecham

  31. Kreider MS, Knox S, Gardiner D, et al. A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson’s disease [abstract]. Neurology 1996; 46: A475

    Google Scholar 

  32. Duvoisin RC, Yahr MD, Cote LD. Pyridoxine reversal of L-dopa effects in parkinsonism [letter]. Trans Am Neurol Ass 1969; 94: 81

    CAS  Google Scholar 

  33. Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 1987; 21: 584–8

    Article  PubMed  CAS  Google Scholar 

  34. Juncos JJ. Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol Clin North Am 1992; 10: 487–509

    CAS  Google Scholar 

  35. Leon AS, Spiegel HE. The effect of an antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972; 12: 263–7

    PubMed  CAS  Google Scholar 

  36. Malcolm SL, Allen JG, Bird H, et al. Single dose pharmacokinetics of Madopar HBS in patients and the effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987: 27: 28–35

    Article  PubMed  Google Scholar 

  37. Campbell NRC, Hasinoff B, Chernenko G, et al. The effect of ferrous sulfate and pH on L-dopa absorption. Can J Physiol Pharmacol 1990; 68: 603–7

    Article  PubMed  CAS  Google Scholar 

  38. Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989; 45: 220–5

    Article  PubMed  CAS  Google Scholar 

  39. Campbell NRC, Rankine D, Goodridge AE, et al. Sinemetferrous sulphate interaction in patients with Parkinson’s disease. Br J Clin Pharmacol 1990; 30: 599–605

    Article  PubMed  CAS  Google Scholar 

  40. Berkowitz DM, McCallum RW Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980; 27: 415–20

    Article  Google Scholar 

  41. Groden BM. Parkinsonism occurring with methyldopa treatment [letter]. BMJ 1963; 2: 1001

    Article  Google Scholar 

  42. Peastin MJT. Parkinsonism associated with alpha-methyldopa therapy [letter]. BMJ 1964; 2: 168

    Article  Google Scholar 

  43. Strang RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966; 95: 928–9

    PubMed  CAS  Google Scholar 

  44. Rosenblum AM, Montgomery EB. Exacerbation of parkinsonism by methyldopa. J Am Med 1980; 244: 2727–8

    CAS  Google Scholar 

  45. Gibberd FB, Small E. Interaction between levodopa and methyldopa. BMJ 1973; 2: 90–1

    Article  PubMed  CAS  Google Scholar 

  46. Shoulson I, Chase TN. Clonidine and the antiparkinsonian response to L-dopa or piribedil. Neuropharmacology 1976; 15: 25–7

    Article  PubMed  CAS  Google Scholar 

  47. Bianchine JR, Sunyapridakul L. Interactions between levodopa and other drugs: significance in the treatment of Parkinson’s disease. Drugs 1973; 6: 364–88

    Article  PubMed  CAS  Google Scholar 

  48. Hunt-Fugate AK, Zander J, Lesar TS. Adverse reactions due to dopamine blockade by amoxapine. Pharmacotherapy 1984; 4: 35–9

    PubMed  CAS  Google Scholar 

  49. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase inhibitor without the ‘cheese effect’. Psychopharmacology 1978; 57: 33–8

    Article  PubMed  CAS  Google Scholar 

  50. Edwards M. Adverse interaction of levodopa with tricyclic antidepressants. Practitioner 1982; 226: 1448–9

    Google Scholar 

  51. Morgan JP, Riviera-Calimlim L, Messiha F, et al. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029–34

    Article  PubMed  CAS  Google Scholar 

  52. Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson’s disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69–74

    Article  PubMed  CAS  Google Scholar 

  53. Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson’s Disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69–74

    Article  PubMed  CAS  Google Scholar 

  54. Brion N, Kollenbach K, Marion MH, et al. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992; 15: 229–35

    Article  PubMed  CAS  Google Scholar 

  55. Mizuta E, Kuno S. Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson’s disease. Clin Neuropharmacol 1993; 16: 448–50

    Article  PubMed  CAS  Google Scholar 

  56. Goldberg LI, Whitsett TL. Cardiovascular effects of levodopa. Clin Pharmacol Ther 1971; 12: 376–82

    PubMed  CAS  Google Scholar 

  57. Kissel P, Tridon P, Andre JM. Levodopa-propranolol therapy in parkinsonian tremor [letter]. Lancet 1974; I: 403–4

    Article  Google Scholar 

  58. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The scientific basis for the treatment of Parkinson’s disease. Park Ridge (NJ): Parthenon, 1992: 89–112

    Google Scholar 

  59. Carpentier AF, Bonnet AM, Vidailhet M, et al. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson’s disease. Neurology 1996; 46: 1548–51

    Article  PubMed  CAS  Google Scholar 

  60. Mendez JS, Cotzias GC, Mena I, et al. Diphenylhydantoin blocking of levodopa effects. Arch Neurol 1975; 32: 44–6

    Article  PubMed  CAS  Google Scholar 

  61. Kurth MC, Tetrud JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson’s disease with severe fluctuations: a pilot study. Neurology 1993; 43: 1036–9

    Article  PubMed  CAS  Google Scholar 

  62. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations. Neurology 1993; 43: 1698–703

    Article  PubMed  CAS  Google Scholar 

  63. Pappert EJ, Goetz GC, Niederman F, et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996; 47: 1493–5

    Article  PubMed  CAS  Google Scholar 

  64. Bennett Jr JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson’s disease: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551–5

    Article  PubMed  Google Scholar 

  65. Birkmayer W, Riederer P, Youdim MBH, et al. The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303–26

    Article  PubMed  CAS  Google Scholar 

  66. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–71

    Article  Google Scholar 

  67. Roberts J, Waller DG, O’Shea N, et al. The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Br J Clin Pharmacol 1995; 40: 404–6

    Article  PubMed  CAS  Google Scholar 

  68. Schulzer M, Mak E, Calne DB. The antiparkinsonian effect of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32: 795–8

    Article  PubMed  CAS  Google Scholar 

  69. Insel TR, Roy BF, Cohen RM. Possible development of serotonin syndrome in man. Am J Psychiatry 1982; 139: 954–5

    PubMed  CAS  Google Scholar 

  70. Suchowersky O, de Vries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35: 571–2

    PubMed  CAS  Google Scholar 

  71. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45: 219–23

    Article  PubMed  CAS  Google Scholar 

  72. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction [letter]. Ann Pharmacother 1992; 26: 1300

    PubMed  CAS  Google Scholar 

  73. Monastruc JL, Chamontin B, Senard JM, et al. Pseudopheochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555

    Article  Google Scholar 

  74. Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 1994; 21: 259–61

    PubMed  CAS  Google Scholar 

  75. Janowsky EJ, Risch C, Janowsky DS. Effects of anesthesia on patients taking psychotropic drugs. J Clin Psychopharmachol 1981; 1: 14–20

    Article  CAS  Google Scholar 

  76. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246

    Article  PubMed  CAS  Google Scholar 

  77. Richards GA, Fritz VU, Pincus P, et al. Unusual drug interactions between monamine oxidase inhibitors and tricyclic antidepressants. J Neurol Neurosurg Psychiatry 1987; 50: 1240–1

    Article  PubMed  CAS  Google Scholar 

  78. Tackley RM, Tregakis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anesthesia 1987; 42: 760–3

    Article  CAS  Google Scholar 

  79. Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994; 25: 813–24

    Article  PubMed  CAS  Google Scholar 

  80. Keranen T, Gordin A, Harjla V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145–56

    Article  PubMed  CAS  Google Scholar 

  81. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994; 44: 2685–8

    Google Scholar 

  82. Tedroff J, Hartvig P, Bjurling P, et al. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 1991; 85: 11–7

    Article  CAS  Google Scholar 

  83. Guldberg HC, Marsden CD. Catechol-O-methyltransferase: pharmacological aspects and physiological role [letter]. Pharmacol Rev 1975; 27: 135–206

    PubMed  CAS  Google Scholar 

  84. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. In: Narbayashi H, Nagatsu T, Yangisawa N, et al., editors. Advances in neurology. New York (NY): Raven Press, 1993: 703–6

    Google Scholar 

  85. Factor SA, Friedman JM. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483–96

    Article  PubMed  CAS  Google Scholar 

  86. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993; 150: 169

    PubMed  CAS  Google Scholar 

  87. Miller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; II: 1500

    Article  Google Scholar 

  88. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52: 223–5

    Google Scholar 

  89. Grohmann R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology 1989; 99 Suppl.: S101–4

    Article  PubMed  Google Scholar 

  90. Cobb CD, Anderson CB, Scidel DR. Possible interactions between clozapine and lorazepam. Am J Psychiatry 1991; 148: 1606–7

    PubMed  CAS  Google Scholar 

  91. Syzmananski S, Lieberman JA, Picou D, et al. Acase report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991; 52: 21–2

    Google Scholar 

  92. Lemus CZ, Liberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11: 127–30

    PubMed  CAS  Google Scholar 

  93. Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493–5

    Article  PubMed  Google Scholar 

  94. Wolters ECH, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47: 1085–7

    Article  PubMed  CAS  Google Scholar 

  95. Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease [letter]. Lancet 1994; 344: 681

    Article  PubMed  CAS  Google Scholar 

  96. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556–9

    PubMed  CAS  Google Scholar 

  97. Korczyn AD, Goldberg GJ. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry 1976; 39: 866–9

    Article  PubMed  CAS  Google Scholar 

  98. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850–4

    Article  PubMed  CAS  Google Scholar 

  99. Sempere AP, Duarte J, Cabezas C. Parkinsonism induced by amlodipine. Mov Disord 1995; 10: 115–6

    Article  PubMed  CAS  Google Scholar 

  100. de Mari M, De Blasi R, Lamberti P. Unilateral pallidal lesions after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord 1993; 8: 247–9

    Article  PubMed  Google Scholar 

  101. Lecamwasam D, Syneck B, Moyles K. Chronic lithium neurotoxicity presenting as Parkinson’s disease: a cross-sectional study of patients with 15 years or more on lithium. Int Clin Psychopharmacology 1994; 9: 127–9

    Article  CAS  Google Scholar 

  102. Ejima A, Imamura T, Nakamura S. Manganese intoxication during total parenteral nutrition [letter]. Lancet 1992; 339: 426

    Article  PubMed  CAS  Google Scholar 

  103. Olive JM, Masana L, Gonzalez J. Meperidine and reversible Parkinsonism. Mov Disord 1994; 9: 115–6

    Article  PubMed  CAS  Google Scholar 

  104. Teusink JP, Alexopoulos GS, Shamoian CA. Parkinsonian side effects induced by a monoamine oxidase inhibitor. Am J Psychiatry 1984; 141: 118–9

    PubMed  CAS  Google Scholar 

  105. Ott BR, Lannon MC. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 1992; 15: 322–5

    Article  PubMed  CAS  Google Scholar 

  106. Alves RSC, Barbosa ER, Scaff M. Postvaccinal parkinsonism. Mov Disord 1992; 7: 178–80

    Article  PubMed  CAS  Google Scholar 

  107. Indo T, Ando K. Metoclopramide-induced parkinsonism. Arch Neurol 1982; 39: 494–6

    Article  PubMed  CAS  Google Scholar 

  108. Montagna P, Gabellini AS, Montari I, et al. Parkinsonian syndrome after long-term treatment with clebopride. Mov Disord 1992; 7: 89–90

    Article  PubMed  CAS  Google Scholar 

  109. Mena AM, de Yebenes MJG, Taberno C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995; 18: 410–26

    Article  PubMed  CAS  Google Scholar 

  110. Micheli F, Fernandez Pardel M, Gatto M, et al. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 37: 881–4

    Article  PubMed  CAS  Google Scholar 

  111. Garcia-Albea E, Jimenez-Jimenez FJ, Ayuso-Peralta L, et al. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993; 16: 263–5

    Article  PubMed  CAS  Google Scholar 

  112. Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95–6

    Article  PubMed  CAS  Google Scholar 

  113. Dotti M, Frederico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10: 233–4

    Article  PubMed  CAS  Google Scholar 

  114. Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspective on its method of action. Am J Med 1986 Suppl. 3B: 1-9

  115. LeWitt PA, Walters A, Hening W, et al. Persistent movement disorders induced by buspirone. Mov Disord 1993; 8: 331–4

    Article  PubMed  CAS  Google Scholar 

  116. Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonism in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451–5

    Article  PubMed  CAS  Google Scholar 

  117. Shindler JS, Finnerty GT, Towlson K, et al. Domperidone and levodopa in Parkinson’s disease. Br J Clin Pharmacol 1984; 18: 959–62

    Article  PubMed  CAS  Google Scholar 

  118. Cann PA, Read NW, Holdsworth CD. Galactorrhea as a side-effect of domperidone. BMJ 1983; 286: 1395–6

    Article  PubMed  CAS  Google Scholar 

  119. Friedman A, Sienkiewicz J. Psychotic complications of long term levodopa treatment of Parkinson’s disease. Acta Neurol Scand 1991; 84: 111–3

    Article  PubMed  CAS  Google Scholar 

  120. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991; 12: 283–95

    Article  Google Scholar 

  121. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 47: 1305–8

    Article  Google Scholar 

  122. Merli GJ, Bell RD. Preoperative management of the surgical patient with neurologic disease. Med Clin North Am 1987; 71(3): 511

    PubMed  CAS  Google Scholar 

  123. Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 425–43

    Article  PubMed  CAS  Google Scholar 

  124. Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in PD. Ann Intern Med 1989; 111: 218–22

    PubMed  CAS  Google Scholar 

  125. Solomon D, Solomon D, Albin M. Neurologic syndromes and their disorders with their anesthetic implications. In: Albin MS, editor. Textbook of neuroanesthesia. New York (NY): McGraw Hill, 1997: 409–11

    Google Scholar 

  126. Mets B. Acute dystonia after alfentanil in untreated Parkinson’s disease. Anesth Analg 1991; 72: 557–8

    Article  PubMed  CAS  Google Scholar 

  127. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med 1990; 323: 1177–83

    Article  PubMed  CAS  Google Scholar 

  128. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45; 219–23

    Article  PubMed  CAS  Google Scholar 

  129. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94–104

    Article  PubMed  CAS  Google Scholar 

  130. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983–5

    Article  PubMed  CAS  Google Scholar 

  131. Lappin RI, Auchinloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl JMed 1994; 331: 1021–2

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Columbia College of Physicians and Surgeons, New York, New York, USA

    Arif Dalvi &  Blair Ford

Authors
  1. Arif Dalvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blair Ford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Blair Ford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalvi, A., Ford, B. Antiparkinsonian Agents. Mol Diag Ther 9, 291–310 (1998). https://doi.org/10.2165/00023210-199809040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199809040-00005

Keywords

Search

Navigation